Pilot RCT Testing A Mailing About Sleeping Pills and Cognitive Behavioral Therapy for Insomnia: Impact on Benzodiazepines and Z-Drugs.
| Autor: | Mak, Selene S., Alessi, Cathy A., Kaufmann, Christopher N., Martin, Jennifer L., Mitchell, Michael N., Ulmer, Christi, Lum, Hillary D., McCarthy, Michaela S., Smith, Jason P., Fung, Constance H. |
|---|---|
| Předmět: |
INSOMNIA treatment
BENZODIAZEPINES BENZODIAZEPINE antagonists PAMPHLETS HUMAN services programs MEDICAL prescriptions MEDICAL care of veterans RESEARCH funding STATISTICAL hypothesis testing STATISTICAL sampling PILOT projects LOGISTIC regression analysis FISHER exact test TRANQUILIZING drugs DEPRESCRIBING DESCRIPTIVE statistics CONTROL groups PRE-tests & post-tests ODDS ratio VETERANS TELEPHONES PHYSICIAN practice patterns COGNITIVE therapy COMPARATIVE studies DATA analysis software CONFIDENCE intervals DRUG prescribing |
| Zdroj: | Clinical Gerontologist; May/Jun2024, Vol. 47 Issue 3, p452-463, 12p |
| Abstrakt: | The aim is to pilot a low-touch program for reducing benzodiazepine receptor agonist (BZRA; benzodiazepines, z-drugs) prescriptions among older veterans. Pilot randomized controlled trial consists of 2,009 veterans aged ≥ 65 years who received BZRA prescriptions from a Veterans Health Administration pharmacy (Colorado or Montana) during the prior 18 months. Active: Arm 1 was a mailed brochure about BZRA risks that also included information about a free, online cognitive behavioral therapy for the insomnia (CBTI) program. Arm 2 was a mailed brochure (same as arm 1) and telephone reinforcement call. Control: Arm 3 was a mailed brochure without insomnia treatment information. Active BZRA prescriptions at follow-up (6 and 12 months) were measured. In logistic regression analyses, the odds of BZRA prescription at 6- and 12-month follow-ups were not significantly different for arm 1 or 2 (active) versus arm 3 (control), including models adjusted for demographics and prescription characteristics (p-values >0.36). Although we observed no differences in active BZRA prescriptions, this pilot study provides guidance for conducting a future study, indicating a need for a more potent intervention. A full-scale trial testing an optimized program would provide conclusive results. Mailing information about BZRA risks and CBTI did not affect BZRA prescriptions. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|